Company / R&D Expense
GeneDx Holdings Corp. R&D Expense History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$72.0M
FY2025
5-year range
$45.7M / $105.2M
FY2021-FY2025
Trend
+57.5%
vs FY2024
Sector context
#66 of 105
Health Care
What the data says
At $72M, GeneDx Holdings Corp.'s r&d expense ranks #66 of 105 in the Health Care sector. R&D Expense returned to growth in FY2025 after 3 years of decline, reaching $72M.
Based on SEC 10-K filings.
$72M in FY2025 with a 5-year CAGR of -0.2%.
Improved from $58M to $72M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -5.8%
- 5-Year CAGR
- -0.2%
- 10-Year CAGR
- -
Sector benchmark
#66 of 105 in Health CareTop 63% of 105This company $72.0M Sector average $284.2M
▼
-74.7% below sector average
Key checks
Key Insights
- 5-year CAGR of -0.2%, indicating a declining trend.
- In FY2025, r&d expense increased 57.5% year-over-year.
- Ranks #66 out of 105 companies in the Health Care sector.
- Peak r&d expense was recorded in FY2021.
Company context
Key Data Points
- Altman Z-Score -0.67 (distress zone, below 1.8 threshold)
- Negative profit margin: -17.1%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $72.0M | +57.5% |
| FY2024 | $45.7M | -21.5% |
| FY2023 | $58.3M | -32.4% |
| FY2022 | $86.2M | -18.0% |
| FY2021 | $105.2M | +44.7% |
| FY2020 | $72.7M | +108.2% |
| FY2019 | $34.9M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026